Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept trial of GLPG1205 in moderate to severe ulcerative colitis
2014-001893-32Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing GLPG1205 with Placebo (2 arms). Started Sep 2014; status: completed.
02
Drugs
GLPG1205
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2014-001893-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001893-32.